aimovig
(erenumab-aooe)Amgen Inc
Usage: AIMOVIG is indicated for the preventive treatment of migraines in adults.
Amgen Inc drugs
15 results
amjevita - adalimumab - atto injection
(Adalimumab-Atto)Amgen Incaranesp - darbepoetin alfa injection, solution
(Darbepoetin Alfa)Amgen Incavsola
(infliximab-axxq)Amgen IncUsage: AVSOLA is indicated for reducing signs and symptoms, inducing and maintaining remission in moderately to severely active Crohn's disease (adult and pediatric), ulcerative colitis (adult and pediatric), and other conditions like rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis.bkemv
(eculizumab-aeeb)Amgen IncUsage: BKEMV is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AchR) antibody positive. It is not for Shiga toxin E. coli related HUS.corlanor
(ivabradine)Amgen IncUsage: Corlanor is indicated to reduce hospitalization risk for adults with stable, symptomatic chronic heart failure (left ventricular ejection fraction ≤ 35%) and resting heart rate ≥ 70 bpm. It is also used for pediatric patients aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy.evenity
(romosozumab-aqqg)Amgen IncUsage: EVENITY is indicated for the treatment of osteoporosis in postmenopausal women at high fracture risk, including those with a history of fractures or multiple risk factors, or those intolerant to other therapies. Limitation: use is restricted to 12 monthly doses due to waning effectiveness.imdelltra
(Tarlatamab-dlle)Amgen IncUsage: IMDELLTRA is indicated for treating adult patients with extensive stage small cell lung cancer (ES-SCLC) who have disease progression after platinum-based chemotherapy. Its approval is based on overall response rate and duration, with continued approval dependent on confirming clinical benefit in further studies.imlygic
(talimogene laherparepvec)Amgen IncUsage: IMLYGIC is indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma patients with recurrence after surgery. It does not improve overall survival or affect visceral metastases.lumakras
(sotorasib)Amgen IncUsage: LUMAKRAS is indicated for treating adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior systemic therapy, and for KRAS G12C-mutated metastatic colorectal cancer (mCRC) in combination with panitumumab, following specific chemotherapy treatments.